To further explore the cross-talk between Notch and BCR-ABL, the effect of the Notch inhibitor GSI on BCR-ABL activity was investigated in CD34+ CML primary cells. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.